Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

A new Alzheimer’s drug has been hailed as a major breakthrough after clinical trials showed it could clear the harmful brain ...

A breakthrough new drug could halt the progression of Alzheimer's disease, claim researchers. Trials suggest the drug—called ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...

There are currently estimated to be 982,000 people with some form of dementia, including Alzheimer's in the UK ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

Roche has shared new data from its Alzheimer’s disease (AD) development portfolio at this year’s Alzheimer’s Association ...